Compounds > 7-benzyl 3-thia-7-azabicyclo(3.3.1)nonane
Page last updated: 2024-11-07

7-benzyl 3-thia-7-azabicyclo(3.3.1)nonane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-benzyl 3-thia-7-azabicyclo(3.3.1)nonane: RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID146049
CHEMBL ID611806
SCHEMBL ID9263062
MeSH IDM0123070

Synonyms (11)

Synonym
CHEMBL611806
7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane
7-benzyl 3-thia-7-azabicyclo(3.3.1)nonane
3-thia-7-azabicyclo(3.3.1)nonane, 7-(phenylmethyl)-
brb-i-28
89398-06-1
7-btabn
GGVNYPLCGOIQCO-UHFFFAOYSA-N
SCHEMBL9263062
7-benzyl-7-aza-3-thiabicyclo[3.3.1]nonane
DTXSID401008796

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The acute and subchronic toxic effects of BRB-I-28 (7-benzyl-3-thia-7-azabicyclo[3."( The acute and subchronic toxicity of BRB-I-28, a novel class Ib antiarrhythmic agent, in CD-1 mice.
Berlin, KD; Chandra, AM; Chen, CL; Chen, H; Cowell, RL; Garrison, GL; Kim, S; Lazzara, R; Qualls, CW; Roder, JD; Sangiah, S; Scherlag, BJ, 2000)		0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Extensive metabolism of BRB-I-28 to form metabolites I and II, which have demonstrated much lower antiarrhythmic activities, further supports previously observed pharmacodynamic and pharmacokinetic findings."( Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent.
Alavi, FK; Berlin, KD; Bourne, DW; Chen, CL; Chen, H; Clarke, CR; Couch, KM; Garrison, GL; Roder, JD; Sangiah, S, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID58291Antiarrhythmic property Heart rate (drug free) is compared to Lidocaine using doses (3 and 6 mg/kg).1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID59033Antiarrhythmic property Mean blood pressure(post drug) is compared to Lidocaine using doses(3 and 6 mg/kg)1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID56535Antiarrhythmic property A-V nodal conduction time(drug free) is compared to lidocaine(2) using doses(3 and 6 mg/kg); No effect1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID62943Antiarrhythmic property ventricular effective refractory period(drug free) is compared to lidocaine(2) using doses(3 and 6 mg/kg)1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID60761Antiarrhythmic property is compared to lidocaine(2) using doses(3 and 6 mg/kg). Time required for the ventricular myocardium to undergo depolarization and repolarization ((post drug); No effect1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID58292Antiarrhythmic property Heart rate (post drug) is compared to Lidocaine using doses(3 and 6 mg/kg). system.1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID59032Antiarrhythmic property Mean blood pressure (drug free) is compared to Lidocaine using doses(3 and 6 mg/kg).1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID56659Antiarrhythmic property A-V nodal conduction time(post drug) is compared to lidocaine(2) using dose (3 and 6 mg/kg); No effect1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID60082Antiarrhythmic property Nonsustained ventricular tachycardia is compared to lidocaine(2) using doses(3 and 6 mg/kg)1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID58818Antiarrhythmic properties are compared to lidocaine(2) using doses(3 and 6 mg/kg) measures His-Purkinje conduction time(drug free)1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID62942Antiarrhythmic property Nonsustained ventricular tachycardia is compared to lidocaine(2) using doses(3 and 6 mg/kg)1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID58823Antiarrhythmic property His-Purkinje conduction time(post drug) is compared to lidocaine(2) using doses(3 and 6 mg/kg)1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
AID60763Antiarrhythmic property is compared to lidocaine(2) using doses(3 and 6 mg/kg). Time required for the ventricular myocardium to undergo depolarization and repolarization (drug free); No effect1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperch
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's10 (83.33)18.2507
2000's1 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		2.8940benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
tedisamil
tedisamil : A member of the class of diazabicyclononanes that is (1s,5s)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane] in which the hydrogens at positions 3 and 7 are replaced by cyclopropylmethyl groups. It is a potassium channel blocker and an antiarrhythmic agent currently currently in development for the treatment of atrial fibrillation.		1.9810
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		1.981011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiovascular Stroke
[description not available]		02.6730
Atrioventricular Nodal Re-Entrant Tachycardia
[description not available]		02.3920
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		02.6730
Tachycardia, Ventricular
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).		02.3920
Heart Disease, Ischemic
[description not available]		02.3920
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.3920
Arrhythmia
[description not available]		01.9810
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		01.9810
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210